Published 13 January 2009, doi:10.1136/bmj.b67
Cite this as: BMJ 2009;338:b67

Analysis

NICE and the challenge of cancer drugs

¹ University of Southampton, Southampton SO16 7PX

NICE has introduced new criteria for appraising end of life treatments. James Raftery looks at how they might affect availability by applying them to previously refused drugs

The first 150 words of the full text of this article appear below.

New drugs for cancer are posing problems for the United Kingdom’s National Institute for Health and Clinical Excellence (NICE) and similar agencies internationally. The high price of these drugs is not always accompanied by commensurate improvements in health,¹ and their cost effectiveness (usually measured as cost per quality adjusted life year (QALY)) is consequently poor. The decisions to allow NHS use of trastuzumab (Herceptin) and imatinib (Glivec) pushed NICE’s cost effectiveness threshold above its notional £30 000 (34 000; $46 000) per QALY.² These decisions took place against a background of legal action by patients, attendant publicity, and political discomfort.

In the second half of last year NICE provisionally rejected six cancer drugs on grounds of their high cost per QALY. When it became clear that patients who wished to purchase these drugs privately would be denied free NHS care, a political crisis became likely.³ This prompted the Richards . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Economics of biological therapies

Christopher J Kelly and Fraz A Mir
BMJ 2009 339: b3276. [Extract] [Full Text]

NICE at 10

Fiona Godlee
BMJ 2009 338: b344. [Extract] [Full Text]

Should NICE’s threshold range for cost per QALY be raised? No

James Raftery
BMJ 2009 338: b185. [Extract] [Full Text]

Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study

A H Miners, Martina Garau, Dogan Fidan, and A J Fischer
BMJ 2005 330: 65. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Yabroff, K. R., Schrag, D. (2009). Challenges and Opportunities for Use of Cost-Effectiveness Analysis. JNCI J Natl Cancer Inst 101: 1161-1163 [Full text]  
• Kelly, C. J, Mir, F. A (2009). Economics of biological therapies. BMJ 339: b3276-b3276 [Full text]  
• Raftery, J. (2009). Should NICE's threshold range for cost per QALY be raised? No. BMJ 338: b185-b185 [Full text]  

Rapid Responses:

Read all Rapid Responses

Cancer drugs too challenging?

Terry J Hamblin
bmj.com, 31 Jan 2009 [Full text]

Online poll

Find out more on doc2doc >>